

NIHR CRN High Level Objectives Year End Performance Report - 2015/16

Public Version: Version 1 13 June 2016



**Delivering research to make patients,
and the NHS, better**

Preface

Scope of the NIHR CRN HLOs Annual Performance Summary Report

This document sets out the NIHR Clinical Research Network's (NIHR CRN) annual performance against its High Level Objectives (HLOs) for the period 1 April 2015 to 31 March 2016, and includes a refreshed data set for Quarter 3 (1 October to 31 December 2015), Quarter 2 (1 July to 30 September 2015) and Quarter 1 (1 April to 30 June 2015). Performance is summarised in Table 1.

This document is produced by the CRN Coordinating Centre, which is responsible for collating and publishing performance data for the NIHR CRN as a whole.

The (HLOs) are the Network's national, overarching objectives for research delivery in the NHS; these are defined in Table 2. The HLOs form one element of the suite of performance indicators which are used to assess the Network's performance. Performance against the other elements of the Network's Performance Framework (Clinical Research Network Specialty Objectives, Host Performance Indicators and Operating Framework Compliance Indicators) will be reported on an annual basis to the Department of Health.

The information presented represents the most complete information available at the time of publication. The main source of annual performance information is through the Central Portfolio Management System (CPMS) which went live on the 31 March 2016.

The data presented in this document may be quoted in presentations and papers. However, we ask that the title and issue date of the report are used, to avoid any confusion about the period to which the figures relate and the time at which the data were reported.

Red/Amber/Green (RAG) ratings

The RAG thresholds used throughout this section are:

- Red: less than 90% of the performance target
- Amber: 90% or more of the performance target but less than 100% of the performance target
- Green: 100% or more of the performance target

For the purposes of performance reporting decimal places are rounded up or down to the nearest whole number.

Further information

For feedback on, or queries relating to, the information contained in this document, please contact:

Amber O'Malley, Head of Performance Management

CRN Coordinating Centre

Email: Amber.O'Malley@nhr.ac.uk

Telephone: 0113 343 0313

Table 1. High Level Objectives Performance Summary Data for 2015/16 (1 April 2015 – 31 March 2016)

Objective	2015/16 Performance							2011/12 performance	2012/13 performance	2013/14 performance	2014/15 performance
	2015/16 Annual Target	Quarter 1 Refreshed in Quarter 4 [1]	Quarter 2 Refreshed in Quarter 4 [1]	Quarter 3 Refreshed in Quarter 4 [1]	Quarter 4	Annual Performance	Difference from annual target				
1	650,000	153,048	165,489	151,745	135,314	605,596	-7%	595,540	637,974	604,216	618,453
2A	80%	66%	63%	68%	65%	65%	-19%	45%	58%	73%	63%
2B [2]	80%	82%	80%	72%	71%	76%	-5%	41%	76%	78%	76%
3A	600	159	161	207	123	650	8%	388	455	533	623
3B	75%	76%	63%	145%	72%	85%	13%	73%	75%	82%	82%
4	80%	83%	80%	77%	76%	79%	-1%	24%	45%	77%	83%
5A	80%	53%	70%	70%	56%	63%	-23%	61%	59%	58%	63%
5B	80%	46%	44%	48%	44%	46%	-43%	32%	36%	44%	50%
6A	99%	98%	100%	100%	100%	100%	1%	99%	99%	100%	98%
6B	70%	66%	70%	72%	74%	74%	6%	61%	62%	86%	78%
6C	25%	16%	28%	35%	42%	42%	68%	Not available	Not available	Not available	41%
7	13,500	7,167	7,447	14,064	6,134	34,812	158%	13,137	11,859	13,583	21,449

[1] Prior to 2015/16 recruitment data was refreshed on an annual basis only. Since 1 April 2015 recruitment data is refreshed on a quarterly basis, therefore the refreshed data presented for a particular quarter may differ to that previously presented for the same quarter.

[2] HLO 2B now combines the previous HLOs 2B and 2C. HLO 5B combines the previous HLOs 5B and 5C. Performance data prior to 2013/14 has been recalculated to account for this.

RAG ratings are against the annual performance target unless otherwise specified.

Where objectives were new for 2014/15 and 2015/16 (3A, 6B, 7) and data is available, performance from 2011/12, 2012/13 and 2013/14 is provided for information but not RAG-rated as no target was in place for those years.

Performance Analysis

HLO 1 While recruitment of participants into NIHR CRN Portfolio studies exceeded 600,000 (605,596), this was lower than 2014/15 and below the 650,000 target (HLO 1). Despite the numbers of new and open studies increasing, the number of observational studies has decreased. This is coupled with the evolving profile of studies on the NIHR CRN Portfolio, including increased numbers of complex interventional studies with lower sample sizes. In 2014/15 the median study sample size fell to 100 compared to 160 in 2008/09. This highlights some of the challenges associated with meeting the recruitment target of 650,000 participants.

HLO 2A The proportion of commercial contract studies achieving recruitment to time and target in 2015/16 is 65%. Performance has increased gradually each quarter in 2015/16, as the CRN works through its performance management plan to improve delivery to time and target. This will continue to be the priority for the NIHR CRN in 2016/17.

HLO 2B The proportion of non-commercial studies achieving recruitment to time and target in 2015/16 is 76%. The CRNCC has focused on improving the data quality for all studies closing in 2015/16 and performance has remained the same as last year. Improving delivery to time and target continues to be the priority for the NIHR CRN in 2016/17.

HLO 3A 650 new commercial contract studies were added to the NIHR CRN Portfolio in 2015/16. The number of new commercial contract studies in 2015/16 is at an all time high. This percentage annual increase has been consistently delivered for the last six years, with twice as many new studies supported this year compared to 2010/11 (650 compared to 324).

HLO 3B The percentage of commercial contract studies supported by the NIHR CRN, when compared to the total number of commercial MHRA CTA approvals for Phase II-IV studies, has been delivered above target for a fourth year. Variance in the number of Clinical Trial Authorisation (CTA) approvals coupled with the timing of actual entry onto the NIHR CRN Portfolio can affect the percentage quarter on quarter, but we have achieved 85%, exceeding the annual target of 75%.

HLO 4 79% of eligible studies obtained all NHS permissions through CSP within 40 calendar days (from receipt of a valid complete application by NIHR CRN) at all study sites in 2015/16. Performance has been sustained despite the transition of the NHS Research Management & Governance to HRA Approval and the decommissioning of the NIHR Coordinated System for gaining NHS Permission (CSP).

HLO 5A 63% of commercial contract studies achieved first participant recruited within 30 calendar days in 2015/16. The importance of delivering against the NIHR Performance in Initiating and Delivering Research (PID) targets has continued to focus sites on rapid first participant recruitment. HLO 5A has been aligned with PID reporting in 2016/17.

HLO 5B 46% of non-commercial studies achieved first participant recruited within 30 calendar days in 2015/16. The importance of delivering

against the NIHR PID targets has continued to focus sites on rapid first participant recruitment. HLO 5B has been aligned with PID reporting in 2016/17.

HLO 6A 100% of NHS Trusts recruited into NIHR CRN Portfolio studies in 2015/16. This is a fantastic achievement and reflects that people have the opportunity to access clinical research opportunities in every NHS Trust.

HLO 6B 74% of NHS Trusts recruited to commercial contract studies in 2015/16, which exceeds the 70% annual target. While the data shows a slight reduction in the number of NHS Trusts involved in commercial research from 2014/15, there has been a continued increase in the number of new studies supported by the NIHR CRN.

HLO 6C 42% of General Medical Practices recruited one or more participants into NIHR CRN Portfolio studies in 2015/16. Any GP practice that has actively recruited to NIHR CRN Portfolio studies within 2015/16, is included in this metric, and we have managed to significantly exceed the 25% annual target.

HLO 7 34,812 participants were recruited into Dementias and Neurodegeneration (DeNDRoN) Specialty studies within 2015/16. This significantly surpasses the annual target of 13,500 participants, with increasing numbers of people recruited through Join Dementia Research.

Table 2. NIHR CRN High Level Objectives 2015/16

Objective		Measure	Target
1	Increase the number of participants recruited into NIHR CRN Portfolio studies	Number of participants recruited in a reporting year into NIHR CRN Portfolio studies	650,000
2	Increase the proportion of studies in the NIHR CRN Portfolio delivering to recruitment target and time	A: Proportion of commercial contract studies achieving or surpassing their recruitment target during their planned recruitment period, at confirmed Network sites	80%
		B: Proportion of non-commercial studies achieving or surpassing their recruitment target during their planned recruitment period	80%
3	Increase the number of commercial contract studies delivered through the NIHR CRN	A: Number of new commercial contract studies entering the NIHR CRN Portfolio	600
		B: Number of new commercial contract studies entering the NIHR CRN Portfolio as a percentage of the total commercial MHRA) CTA approvals for Phase II–IV studies	75%
4	Reduce the time taken for eligible studies to achieve NHS Permission through CSP	Proportion of eligible studies obtaining all NHS Permissions within 40 calendar days (from receipt of a valid complete application by NIHR CRN)	80%
5	Reduce the time taken to recruit first participant into NIHR CRN Portfolio studies	A: Proportion of commercial contract studies achieving first participant recruited within 30 calendar days of NHS Permission being issued or First Network Site Initiation Visit, at confirmed Network sites	80%
		B: Proportion of non-commercial studies achieving first participant recruited within 30 calendar days of NHS Permission being issued	80%
6	Increase NHS participation in NIHR	A: Proportion of NHS Trusts recruiting each year into NIHR CRN portfolio studies	99%

	CRN Portfolio studies	B: Proportion of NHS Trusts recruiting each year into NIHR CRN portfolio commercial contract studies	70%
		C: Proportion of General Medical Practices recruiting each year into NIHR CRN portfolio studies	25%
7	Increase the number of participants recruited into Dementias and Neurodegeneration (DeNDRoN) studies on the NIHR CRN Portfolio	Number of participants recruited into DeNDRoN studies on the NIHR CRN portfolio	13,500